Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19364297 | FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION | October 2025 | March 2026 | Allow | 4 | 0 | 0 | Yes | No |
| 18637522 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | April 2024 | July 2025 | Allow | 15 | 1 | 0 | No | No |
| 18631672 | ANTIBODIES BINDING PD-1 AND USES THEREOF | April 2024 | March 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18441469 | BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEREOF | February 2024 | November 2025 | Allow | 21 | 1 | 0 | No | No |
| 18435815 | HUMAN ANTIBODIES TO ARTEMIN AND METHODS OF USE THEREOF | February 2024 | May 2025 | Allow | 15 | 1 | 0 | No | No |
| 18423089 | METHODS OF TREATING TUMORS | January 2024 | October 2025 | Allow | 21 | 3 | 1 | Yes | No |
| 18417708 | MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS | January 2024 | September 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18537578 | METHODS FOR TREATING PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA | December 2023 | June 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18516397 | COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1 | November 2023 | March 2026 | Abandon | 28 | 2 | 0 | No | No |
| 18493744 | ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEIN | October 2023 | July 2025 | Abandon | 20 | 1 | 0 | Yes | No |
| 18492028 | ENGINEERED ANTI-IL-2 ANTIBODIES | October 2023 | December 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18466722 | ILT-BINDING AGENTS AND METHODS OF USE THEREOF | September 2023 | May 2025 | Allow | 20 | 1 | 0 | No | No |
| 18455181 | ANTI-CD200R1 ANTIBODIES AND METHODS OF USE THEREOF | August 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18446782 | SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19 | August 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18364285 | ILT3-BINDING AGENTS AND METHODS OF USE THEREOF | August 2023 | August 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18349438 | ANTI-MUC1 ANTIBODY-DRUG CONJUGATE | July 2023 | December 2024 | Allow | 17 | 1 | 0 | No | No |
| 18347361 | BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 | July 2023 | April 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18069317 | METHODS OF TREATING CANCER USING NEURONAL ACTIVITY INHIBITING AGENTS | December 2022 | December 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17913182 | BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2 | September 2022 | October 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17759800 | NOVEL LILRB2 ANTIBODIES AND USES THEREOF | July 2022 | December 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17795960 | ENGINEERED ANTI-IL-2 ANTIBODIES | July 2022 | December 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17873864 | NOVEL POLYPEPTIDES AND USES THEREOF | July 2022 | February 2025 | Allow | 31 | 5 | 1 | No | No |
| 17813122 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | July 2022 | September 2025 | Allow | 38 | 3 | 1 | Yes | No |
| 17812950 | DOSAGE REGIMES | July 2022 | February 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17812159 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE | July 2022 | February 2025 | Abandon | 31 | 4 | 1 | No | No |
| 17827630 | Sequences of anti-ecto-5'-nucleotidase antibodies | May 2022 | November 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17775942 | HUMAN MONOCLONAL ANTIBODIES TO HANTAVIRUS AND METHODS OF USE THEREFORE | May 2022 | September 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17775706 | ANTI-HUMAN CRIPTO-1 ANTIBODY | May 2022 | October 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17662573 | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND METHODS OF USE THEREOF | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17775279 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17775167 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING | May 2022 | December 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17718771 | ANTI AQP3 MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF | April 2022 | December 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17716530 | METHOD FOR TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR | April 2022 | April 2025 | Abandon | 36 | 3 | 1 | No | No |
| 17763621 | HUMANIZED MONOCLONAL ANTIBODY FOR 2019 NOVEL CORONAVIRUS AND USE THEREOF | March 2022 | August 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17763113 | A NOVEL ANTI-PD-L1/ANTI-LAG-3 BISPECIFIC ANTIBODY AND USES THEREOF | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17642674 | ZIKA ANTIBODIES AND THEIR USE | March 2022 | November 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17687558 | EPHA2 ANTIBODIES | March 2022 | July 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17686666 | ANTI-CD73 ANTIBODIES AND USE THEREOF | March 2022 | August 2024 | Allow | 29 | 3 | 1 | Yes | No |
| 17685423 | METHODS FOR THE TREATMENT OF GPP | March 2022 | December 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17580547 | METHODS AND COMPOSITIONS RELATING TO ADENOSINE RECEPTORS | January 2022 | September 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17625445 | NOVEL FUSION PROTEIN AND USE OF SAME | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17562961 | Antibody Compositions and Methods of Use Thereof | December 2021 | November 2024 | Abandon | 35 | 3 | 1 | Yes | No |
| 17611318 | NOVEL MODIFIED IMMUNOGLOBULIN FC-FUSION PROTEIN AND USE THEREOF | November 2021 | October 2025 | Allow | 47 | 1 | 0 | Yes | No |
| 17508714 | METHOD FOR IMPROVING NEUROLOGICAL FUNCTION IN MPSI AND MPSII AND OTHER NEUROLOGICAL DISORDERS | October 2021 | October 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17507618 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | October 2021 | September 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17501846 | BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28 | October 2021 | August 2025 | Abandon | 46 | 4 | 1 | No | No |
| 17416846 | FOOD AND ADDITIVE COMPOSITIONS, AND ALSO USES OF LIGNIN AND THE ADDITIVE COMPOSITION | June 2021 | February 2026 | Abandon | 56 | 4 | 1 | No | No |
| 17323884 | MAGEB2 BINDING CONSTRUCTS | May 2021 | January 2024 | Allow | 32 | 1 | 1 | No | No |
| 17292888 | IMMUNOGENIC PEPTIDES WITH NEW OXIDOREDUCTASE MOTIFS | May 2021 | August 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17315061 | COMPOSITIONS AND METHODS FOR PREDICTING THERAPEUTIC OUTCOME | May 2021 | August 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17290961 | B-CELL ACTIVATING CD73 ANTIBODIES | May 2021 | November 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17244785 | METHODS OF TREATING MULTIPLE MYELOMA | April 2021 | October 2024 | Abandon | 42 | 3 | 0 | No | Yes |
| 17232263 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR KIDNEY CANCER | April 2021 | October 2025 | Abandon | 54 | 2 | 1 | Yes | No |
| 17265506 | TREATMENT OF IMMUNE DISEASES BY MEANS OF THE ANTIBODY-MEDIATED NEUTRALIZATION OF SPECIFIC INTESTINAL BACTERIA | February 2021 | November 2024 | Abandon | 46 | 3 | 0 | No | No |
| 17264760 | USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR | January 2021 | November 2025 | Abandon | 57 | 4 | 0 | No | No |
| 17261245 | INHIBITION OF CYSTATINS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | January 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17131221 | IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2 | December 2020 | May 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 17252482 | METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER | December 2020 | August 2025 | Abandon | 56 | 4 | 1 | No | No |
| 17251497 | BIOLUMINESCENT MARKERS OF NEURAL ACTIVITY | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17116699 | Stabilized Formulations Containing Anti-CD20 x Anti-CD3 Bispecific Antibodies | December 2020 | June 2025 | Abandon | 54 | 4 | 0 | No | Yes |
| 17112768 | FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION | December 2020 | February 2026 | Allow | 60 | 5 | 1 | Yes | Yes |
| 17055279 | ANTIBODIES AGAINST LIF AND DOSAGE FORMS THEREOF | November 2020 | September 2025 | Abandon | 58 | 4 | 1 | Yes | No |
| 17081356 | ANTIBODY CARRIER BASED ON GOLD NANOPARTICLE-APTAMER CONJUGATE AND METHOD OF PREPARING THE SAME | October 2020 | November 2025 | Abandon | 60 | 7 | 1 | Yes | No |
| 17048508 | BINDING MOLECULES | October 2020 | January 2025 | Abandon | 51 | 1 | 0 | No | No |
| 17046341 | METHOD FOR TREATING AUTOIMMUNE DISEASE | October 2020 | October 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 16959378 | PEPTIDE IMMUNOGENS AND FORMULATIONS THEREOF TARGETING MEMBRANE-BOUND IgE FOR TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | June 2020 | January 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 16955984 | ASSAY, METHOD AND TREATMENT OF ALPHA-SYNUCLEINOPATHIES | June 2020 | March 2026 | Abandon | 60 | 6 | 0 | Yes | No |
| 16767189 | METHODS OF PREVENTING OR TREATING NEUROGENIC SHOCK | May 2020 | July 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16760899 | CD47 ANTIGEN-BINDING MOLECULES | April 2020 | November 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16781161 | METHOD FOR ACQUIRING INFORMATION ON ANALYTE | February 2020 | August 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16461430 | METHODS FOR TREATING PERIPHERAL NERVE INJURY | May 2019 | May 2022 | Abandon | 36 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BENAVIDES, JENNIFER ANN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BENAVIDES, JENNIFER ANN works in Art Unit 1675 and has examined 30 patent applications in our dataset. With an allowance rate of 20.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 54 months.
Examiner BENAVIDES, JENNIFER ANN's allowance rate of 20.0% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BENAVIDES, JENNIFER ANN receive 3.00 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BENAVIDES, JENNIFER ANN is 54 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.1% benefit to allowance rate for applications examined by BENAVIDES, JENNIFER ANN. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.1% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.